Mortality of Candidozyma auris Candidemia Compared with Non-C. auris Candidemia

Candidozyma auris (formerly Candida auris) is frequently multidrug-resistant, resulting in limited treatment options and high mortality. Comparable mortality between C. auris candidemia and non-C. auris candidemia in recent studies requires confirmation in the Middle East after adjustment for confounders. This study aimed to compare mortality rates between patients with candidemia by C. auris and non-C. auris Candida species. We retrospectively analyzed 94 cases with candidemia between January 2019 and October 2025, including C. auris candidemia (n = 30) and non-C. auris candidemia (n = 64). Inverse probability weighting was used to balance baseline confounders between groups. The primary analysis used a weighted Cox proportional hazards model. Patients in the C. auris group had more comorbidities, greater healthcare exposure, and longer hospital stays. Crude 30-day all-cause cumulative mortality was comparable between the C. auris and non-C. auris groups (log-rank test, p = 0.8). The 30-day mortality of C. auris candidemia was similar to that of non-C. auris candidemia (adjusted HR 0.40; 95% CI 0.16-1.04; p = 0.060). Large multicenter studies involving diverse populations across different regions are warranted to validate these findings.